The first monoclonal antibody combination product for preventing and treating COVID-19 has been approved for use in the UK

AdobeStock_353368940

Following a thorough evidence review, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ronapreve as the first monoclonal antibody treatment for COVID-19 in the UK.

The drug, developed by Regeneron/Roche, is administered either by injection or infusion. It acts at the lining of the respiratory system, where it binds tightly to the coronavirus and prevents it from gaining access to the cells of the respiratory system.

Clinical trial data assessed by a dedicated team of MHRA scientists and clinicians has shown that Ronapreve may be used to prevent infection, promote resolution of symptoms of acute COVID-19 infection, and can reduce the likelihood of being admitted to hospital due to COVID-19.

Health and Social Care Secretary, Sajid Javid, said: ‘This is fantastic news from the independent medicines regulator and means the UK has approved its first therapeutic designed specifically for COVID-19.

This treatment will be a significant addition to our armoury to tackle COVID-19—in addition to our world-renowned vaccination programme and life-saving therapeutics dexamethasone and tocilizumab. We are now working at pace with the NHS and expert clinicians to ensure this treatment can be rolled out to NHS patients as soon as possible.’